Live

Mitochondria, potential new therapeutic targets in pancreatic cancer - CRCM PhD Day 2021 will take place on May 28 2021 - La cycline A2, qui maintient l'homéostasie du côlon, est un facteur de pronostic dans le cancer colorectal -

Dec 2019 Medecine sciences : M/S

[Bispecific antibodies, novel therapeutic candidates harnessing the immune system].

Authors

Chames P, Wurch T

Summary

Over the past ten years, an increased knowledge of tumor biology and immunology allowed the design and development of novel therapeutic antibody and protein scaffold formats, where bispecific antibodies (Abs) play a major role. The latter molecules can (1) bring novel pharmacological properties through the co-engagement of two targets, (2) increase the safety profile as compared to a combination of two antibodies thanks to a targeted relocation to the tumor and (3) reduce development and manufacturing costs associated with single drug product. This review analyzes the different bispecific antibodies and scaffolds described in the field of immuno-oncology, their structure and major pharmacological and physico-chemical properties.

Read the article